SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (Nasdaq:PDII), a provider of commercialization services to the biopharmaceutical industry, today announced that it has signed an agreement with a top-five pharmaceutical company which is expected to generate approximately $23 million in revenue for PDI over its one year term. This new dedicated contract sales engagement targets primary care physicians and specialty audiences.
